[{"address1": "7750 El Camino Real", "address2": "Suite 2A", "city": "Carlsbad", "state": "CA", "zip": "92009", "country": "United States", "phone": "858 704 4900", "website": "https://www.palisadebio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.", "fullTimeEmployees": 9, "maxAge": 86400, "priceHint": 4, "previousClose": 4.76, "open": 4.6766, "dayLow": 4.6766, "dayHigh": 4.81, "regularMarketPreviousClose": 4.76, "regularMarketOpen": 4.6766, "regularMarketDayLow": 4.6766, "regularMarketDayHigh": 4.81, "beta": 1.291, "forwardPE": -0.54597044, "volume": 28387, "regularMarketVolume": 28387, "averageVolume": 1144583, "averageVolume10days": 22890, "averageDailyVolume10Day": 22890, "bid": 3.44, "ask": 6.02, "bidSize": 200, "askSize": 200, "marketCap": 4504093, "fiftyTwoWeekLow": 3.82, "fiftyTwoWeekHigh": 36.6, "priceToSalesTrailing12Months": "Infinity", "fiftyDayAverage": 5.5466, "twoHundredDayAverage": 7.384, "currency": "USD", "enterpriseValue": -6581327, "floatShares": 830839, "sharesOutstanding": 936402, "sharesShort": 35226, "sharesShortPriorMonth": 34516, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.0376, "heldPercentInsiders": 0.028889999, "heldPercentInstitutions": 0.10572, "shortRatio": 0.01, "shortPercentOfFloat": 0.0433, "impliedSharesOutstanding": 942701, "bookValue": 11.82, "priceToBook": 0.4069374, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -13503000, "trailingEps": -23.46, "forwardEps": -8.81, "lastSplitFactor": "1:15", "lastSplitDate": 1712534400, "enterpriseToEbitda": 0.471, "52WeekChange": -0.8068273, "SandP52WeekChange": 0.26238096, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "PALI", "underlyingSymbol": "PALI", "shortName": "Palisade Bio, Inc.", "longName": "Palisade Bio, Inc.", "firstTradeDateEpochUtc": 1175261400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "48a6a4f2-9a74-360b-918d-da0f22330672", "messageBoardId": "finmb_244367385", "gmtOffSetMilliseconds": -14400000, "currentPrice": 4.81, "targetHighPrice": 45.0, "targetLowPrice": 22.5, "targetMeanPrice": 33.75, "targetMedianPrice": 33.75, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 2, "totalCash": 11276000, "totalCashPerShare": 12.027, "ebitda": -13985000, "totalDebt": 183000, "quickRatio": 4.633, "currentRatio": 4.869, "debtToEquity": 1.818, "returnOnAssets": -0.62643003, "returnOnEquity": -1.1328399, "freeCashflow": -6693125, "operatingCashflow": -10787000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]